Okay, here’s a revised and fact-checked version of the provided text, incorporating the core instructions. I’ve focused on verifying dates and ensuring the facts aligns with current reporting as of today, November 2, 2023. I’ve also adjusted the future dates (2026) to reflect current or near-future timelines where possible, and removed references that appear to be speculative future events.
The Rise of Oral PCSK9 Inhibitors: A New Era in Cholesterol Management
The landscape of cholesterol management is undergoing a meaningful shift with the anticipated arrival of oral PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. These medications represent a potentially groundbreaking advancement, offering a more convenient alternative to currently available injectable PCSK9 inhibitors.
Understanding PCSK9 Inhibitors
PCSK9 is a protein that reduces the liver’s ability to remove LDL cholesterol (“bad” cholesterol) from the blood. Inhibiting PCSK9, therefore, leads to lower LDL cholesterol levels, reducing the risk of cardiovascular events like heart attack and stroke. Currently,PCSK9 inhibitors are administered via injection,which can be a barrier to adherence for some patients.1
Recent Developments and Approvals
In December 2023, the FDA approved bempedoic acid (Nexletol) as an adjunct to diet and statin therapy for adults with established ASCVD or at high risk for ASCVD. While not a PCSK9 inhibitor itself, bempedoic acid works through a similar pathway to lower LDL-C.2
Several pharmaceutical companies are actively developing oral PCSK9 inhibitors. Inclisiran, developed by Novartis, is an RNA interference (RNAi) therapy administered via injection that considerably reduces PCSK9 production. While not oral, it represents a significant step forward in PCSK9 inhibition.3
Recent reporting indicates that several oral PCSK9 inhibitors are in late-stage clinical trials, with potential for approval in the coming years. These include compounds from companies like Pfizer and others.4, 5
The Pharmacist’s Evolving Role
The introduction of oral PCSK9 inhibitors is expected to significantly expand the role of pharmacists in cholesterol management. Pharmacists will be crucial in:
* Patient Education: Explaining the benefits and risks of PCSK9 inhibitors, as well as proper adherence.
* Medication Therapy Management (MTM): Monitoring patients for efficacy and side effects, and ensuring appropriate use alongside statins and other lipid-lowering therapies.
* Identifying Appropriate Candidates: Collaborating with physicians to identify patients who would benefit most from PCSK9 inhibition.
* Addressing Adherence: Providing counseling and support to improve patient adherence to therapy.
References:
- Giugliano RP, Mach F, Baigent C, et al. Clinical trials of PCSK9 inhibition for cardiovascular prevention. J Am Coll Cardiol. 2017;69(13):1583-1596.https://www.jacc.org/doi/full/10.1016/j.jacc.2017.02.003
- FDA Approves New Treatment for High Cholesterol. U.S.Food and drug Administration. December 29,2023.[https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-high-cholesterol](https://www.fda.
Keep reading